FDA approves rapid, inexpensive saliva test for novel coronavirus

News: United States Food and Drug Administration(FDA) has approved SalivaDirect test for Covid19.


  • Who developed the test? The SalivaDirect test has been developed by researchers from Yale School of Public Health in partnership with the National Basketball Association(NBA).
  • How is the test different? SalivaDirect test uses saliva samples as opposed to the more invasive nasopharyngeal swabs.
  • What is the testing Procedure? The collection and testing of saliva samples involves three steps — collecting saliva without preservative buffers, proteinase K treatment and heat inactivation and dualplex RT-qPCR virus detection.
  • Significance:
    • The testing can detect the virus even when the number of virus copies in the saliva sample is as low as 6-12 copies per microlitre.
    • The test is affordable when compared to other tests of Covid-19.
    • The testing makes sample collection non-invasive and reduces the need for trained healthcare workers to collect the samples, reducing the risk of infection during collection.
    • This test is more accurate when compared to tests using nasopharyngeal swabs which sometimes leads to false negative results due to errors at the time of sample collection.
Print Friendly and PDF